BMY is looking to expand its pipeline/portfolio as the legacy portfolio is being adversely impacted due to continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane. Per the terms ...

Bristol-Myers Squibb’s Sprycel (dasatinib) and Novartis’ Tasigna (nilotinib), which made more than $1 billion in the first half of this year. If approved, asciminib would beef up Novartis ...

MG is going from strength to strength in the UK, with new models appearing left, right and centre, including this latest ZS. From the humble MG3 hybrid supermini to the head-turning Cyberster ...

The first line regimen approved in the UK is Gleevec (imatinib) followed by Tasigna (nilotinib) and Sprycel (dasatinib) as a second and third line of therapy respectively. But TKIs are not able to ...

of patients were able to tolerate the EOD therapy (mean dose 5.6 mg) regimen for 4 ± 2.9 (mean ± SD) months. Mean LDL-C decreased 34.5% (p < 0.001) in the patients who tolerated the regimen ...

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug FBI Arrests Chinese Researchers For Attempting To Smuggle 'Potential Agroterrorism Weapon' — Kash ...